[Alpha Tau in Alpha Tau] Alpha Tau reports new positive results in two upcoming presentations at ASCO GI 2026 Symposium showcasing immune-preservation and high disease control in Montreal Pancreatic Cancer Alpha DaRT® study

Jerusalem, January 6, 2026 – Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^® today announced the release of final results from its first-in-human pancreatic cancer study in Montreal, Canada exploring the use of Alpha DaRT in treating pancreatic ductal adenocarcinoma (PDAC). The results have been published as two abstracts and will be presented at the upcoming 2026 ASCO Gastrointestinal Cancers Symposium in San Francisco, January 8 – 10, 2026.

Read more here.